It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACGL’s FA Score shows that 2 FA rating(s) are green whileINBX’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ACGL’s TA Score shows that 4 TA indicator(s) are bullish while INBX’s TA Score has 6 bullish TA indicator(s).
ACGL (@Multi-Line Insurance) experienced а +1.02% price change this week, while INBX (@Biotechnology) price change was +3.61% for the same time period.
The average weekly price growth across all stocks in the @Multi-Line Insurance industry was -0.21%. For the same industry, the average monthly price growth was +2.12%, and the average quarterly price growth was +20.22%.
The average weekly price growth across all stocks in the @Biotechnology industry was +11.02%. For the same industry, the average monthly price growth was +29.50%, and the average quarterly price growth was +16.11%.
ACGL is expected to report earnings on Jul 23, 2025.
INBX is expected to report earnings on Aug 19, 2025.
A multi-line insurance contract bundles together exposures to risk and covers them under a single contract. For providers of such policies, the bundle is a potential risk diversification strategy since their exposure gets spread over several factors, which helps them mitigate a financial burden if a catastrophic event were to occur. Other potential benefits include getting more premiums from including more than one type of insurance in a bundle, and getting a competitive edge by procuring multiple insurance contracts with a customer. Examples of companies in this industry are Berkshire Hathaway (which owns several insurance companies), Chubb Limited, American International Group, Inc. and Sun Life Financial Inc.
@Biotechnology (+11.02% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
ACGL | INBX | ACGL / INBX | |
Capitalization | 34.6B | 216M | 16,019% |
EBITDA | N/A | 1.73B | - |
Gain YTD | -2.220 | -1.234 | 180% |
P/E Ratio | 7.94 | 0.13 | 6,332% |
Revenue | 13.3B | 200K | 6,650,000% |
Total Cash | 8.03B | 217M | 3,699% |
Total Debt | 2.73B | 107M | 2,548% |
ACGL | ||
---|---|---|
OUTLOOK RATING 1..100 | 80 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 82 Overvalued | |
PROFIT vs RISK RATING 1..100 | 11 | |
SMR RATING 1..100 | 93 | |
PRICE GROWTH RATING 1..100 | 59 | |
P/E GROWTH RATING 1..100 | 31 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ACGL | INBX | |
---|---|---|
RSI ODDS (%) | N/A | 3 days ago83% |
Stochastic ODDS (%) | 3 days ago76% | 3 days ago87% |
Momentum ODDS (%) | 3 days ago51% | 3 days ago77% |
MACD ODDS (%) | 3 days ago51% | 4 days ago86% |
TrendWeek ODDS (%) | 3 days ago67% | 3 days ago79% |
TrendMonth ODDS (%) | 3 days ago42% | 3 days ago80% |
Advances ODDS (%) | 19 days ago64% | 5 days ago80% |
Declines ODDS (%) | 10 days ago51% | 9 days ago84% |
BollingerBands ODDS (%) | 3 days ago78% | 3 days ago88% |
Aroon ODDS (%) | 3 days ago61% | 3 days ago82% |
A.I.dvisor indicates that over the last year, ACGL has been closely correlated with ORI. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if ACGL jumps, then ORI could also see price increases.
Ticker / NAME | Correlation To ACGL | 1D Price Change % | ||
---|---|---|---|---|
ACGL | 100% | +0.17% | ||
ORI - ACGL | 73% Closely correlated | +0.35% | ||
AIG - ACGL | 62% Loosely correlated | +0.04% | ||
HIG - ACGL | 61% Loosely correlated | -0.50% | ||
FIHL - ACGL | 52% Loosely correlated | +0.44% | ||
IGIC - ACGL | 42% Loosely correlated | +0.62% | ||
More |
A.I.dvisor indicates that over the last year, INBX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if INBX jumps, then AXON could also see price increases.
Ticker / NAME | Correlation To INBX | 1D Price Change % | ||
---|---|---|---|---|
INBX | 100% | +4.04% | ||
AXON - INBX | 48% Loosely correlated | -0.87% | ||
AKESF - INBX | 45% Loosely correlated | N/A | ||
IMNM - INBX | 41% Loosely correlated | -1.34% | ||
SNTI - INBX | 39% Loosely correlated | -17.99% | ||
ACET - INBX | 39% Loosely correlated | -0.49% | ||
More |